Results 41 to 50 of about 15,884 (195)

Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic Hepatitis B virus infected patients [PDF]

, 2012
Natural killer (NK) cells play a critical role in innate antiviral immunity, but little is known about the impact of antiviral therapy on the frequency of NK cell subsets.
Chi, X., Hou, J., Hu, X., Jin, Q., Lv, J., Niu, J., Pan, Y., Sun, H., Tian, Z., Tu, Z., Xiao, W., Xu, D., Yan, H.   +12 more
core   +3 more sources

Continuous entecavir for treatment-naïve Chinese chronic hepatitis B in the real world setting: the six-year results [PDF]

, 2014
This journal suppl. entitled: 2014 DDW AbstractBACKGROUND: There is a paucity of data on uninterrupted entecavir for treatment-naive chronic hepatitis B (CHB) beyond 5 years.
Fung, J, Ko, MKL, Lai, CL, Lam, YF, Liu, KSH, Mak, LY, Seto, WK, Yuen, RMF   +7 more
core   +1 more source

Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients [PDF]

, 2008
Background To investigate dynamic fluctuations of serum viral load and peripheral T-lymphocyte subpopulations of chronic hepatitis B patients and their correlation during entecavir therapy. Methods Fifty-five patients received entecavir 0.5 mg/d therapy.
Jing You, Hutcha Sriplung, Alan Geater, Virasakdi Chongsuvivatwong, Lin Zhuang, Yun-Li Li, Hua Lei, Jun Liu, Hong-Ying Chen, Bao-Zhang Tang, Jun-Hua Huang, JN Stoop, TI Michalak, N Tulek, U Khettry, TF Baumert, A Bertoletti, DX Liu, JN Stoop, O Franzese, C Boni, C Boni, C Boni, JL Dienstag, HL Tillmann, A Rivkin, RG Gish, EB Keeffe, TT Chang, CL Lai, G Yao, M Sherman, AS Lok, N Leung, RG Gish, JN Stoop, GK Lau, Y Kondo, E Mizukoshi   +38 more
core   +2 more sources

THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS

Alʹmanah Kliničeskoj Mediciny, 2016
Aim: To evaluate retrospectively the efficacy and safety of entecavir in treatment-naïve patients with hepatitis B viral infection.Materials and methods: Based on patient medical documentation, we analyzed the results of clinical, virologic and ...
L. I. Mel'nikova, L. Yu. Il'chenko
doaj   +1 more source

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection [PDF]

, 2013
Introduction: Resistance in nucleoside/nucleotide analog (NA) therapy has always been a challenge in the management of chronic hepatitis B (CHB). Clinical studies: Initially developed for the treatment of HIV infection, early in vitro and clinical ...
Fung, J, Lai, CL, Seto, WK, Yuen, MF
core   +1 more source

The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang, Taoran Geng, Ruirui You, Huiling Xiang, Ying Guo, Xiaohong Gao, Guojun Li, Qun Zhang, Xiaoping Wu, Haifang Cao, Wenhua Zhang, Jia Shang, Jiawei Geng, Lihong Qu, Shuilin Sun, Xiulan Xue, Rui Zhao, Lihua Zhong, Guohong Ge, Yanbin Wang, Jianqi Lian, Ming Liang, Qing Ye, Xiaoyan Wang, Xiaoqing Guo, Dan Xu, Yiqi Yu, Feng Sun, Chao Qiu, Jiming Zhang, Yuxian Huang, Wenhong Zhang, Xiaolong Qi   +32 more
wiley   +1 more source

Effect of entecavir on CD4+ T-cell subpopulations in patients with chronic hepatitis B

Annals of Hepatology, 2016
Background and aims. CD4+ T cells play an important role in response to hepatitis B virus (HBV) infection. We investigated the change in CD4+ T-cell subpopulations and viral load in patients with chronic HBV infection who were treated with entecavir ...
Tian Zhan-Fei, You Zhong-Lan, Hong Yi, Kuang Xue-Mei, Wang Yu-Ming   +4 more
doaj   +1 more source

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

Hepatology Research, EarlyView.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami, Soranobu Ninomiya, Takayasu Ideta, Ayumu Kanbe, Toshihide Maeda, Daisuke Minowa, Daisuke Taguchi, Masaya Kubota, Hiroyasu Sakai, Kenji Imai, Yasuko Yamamoto, Hiroyasu Ito, Kuniaki Saito, Osamu Yoshida, Yoichi Hiasa, Masahito Shimizu   +15 more
wiley   +1 more source

Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis

Frontiers in Pharmacology
ObjectivesTo systematically evaluate the efficacy and safety of tenofovir and entecavir in chronic hepatitis B-related cirrhosis.MethodsA comprehensive search was conducted in databases including PubMed, Web of Science, Embase and Cochrane Library from ...
Lu Cao, Li Li, Lixing Yang, Nan Zhou, Yu Zhang   +4 more
doaj   +1 more source

Auxiliary Liver Graft Can Be Protected From HBV Infection in HBsAg Positive Blood Circulation

Frontiers in Medicine, 2021
Auxiliary grafts have a high risk of Hepatitis B virus (HBV) infection in patients with chronic HBV-related diseases. Hepatitis B virus-related auxiliary partial orthotopic liver transplantation (APOLT) cases were reviewed to show the results of current ...
Lin Wei, Lin Wei, Lin Wei, Hai-Ming Zhang, Hai-Ming Zhang, Hai-Ming Zhang, Chi-Dan Wan, Wei Qu, Wei Qu, Wei Qu, Zhi-Gui Zeng, Zhi-Gui Zeng, Zhi-Gui Zeng, Ying Liu, Ying Liu, Ying Liu, Jun Xiong, Li-Ying Sun, Li-Ying Sun, Li-Ying Sun, Zhi-Jun Zhu, Zhi-Jun Zhu, Zhi-Jun Zhu   +22 more
doaj   +1 more source